Diffusion Pharmaceuticals is a drug-discovery and development company, engages in the commercialization of small-molecule therapeutics to treat serious or life-threatening medical conditions by increasing the amount of oxygen to hypoxic tissues. Its products include trans sodium crocetinate and trans bipolar carotenoids molecules, which are used to treat life-threatening conditions, such as trauma, cancer, stroke, cardiovascular diseases, respiratory disorders, peripheral vascular and arterial diseases, and various other conditions.
TypePublic
HQCharlottesville, US
Founded2001
Size (employees)11 (est)+10%
Websitediffusionpharma.com
Diffusion Pharmaceuticals was founded in 2001 and is headquartered in Charlottesville, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Diffusion Pharmaceuticals

David Kalergis

David Kalergis

Chairman & Chief Executive Officer
Ben Shealy

Ben Shealy

CFO
David Jones

David Jones

Chief Medical Officer
John Gainer

John Gainer

Chief Scientific Officer
Show more

Diffusion Pharmaceuticals Office Locations

Diffusion Pharmaceuticals has an office in Charlottesville
Charlottesville, US (HQ)
400 1317 Carlton Ave
Show all (1)
Report incorrect company information

Diffusion Pharmaceuticals Financials and Metrics

Diffusion Pharmaceuticals Revenue

USD

Net income (Q3, 2018)

(6.7m)

EBIT (Q3, 2018)

7.0m

Market capitalization (17-Jan-2019)

7.7m

Closing stock price (17-Jan-2019)

2.3

Cash (30-Sep-2018)

11.0m
Diffusion Pharmaceuticals's current market capitalization is $7.7 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Revenue

71.7k

General and administrative expense

2.5m11.1m6.2m

R&D expense

3.9m7.3m5.1m

Operating expense total

13.0m6.4m18.3m11.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018

General and administrative expense

339.6k611.8k261.6k847.7k1.9m2.3m3.9m1.6m1.8m1.6m1.7m1.6m

R&D expense

403.4k930.2k1.1m1.4m1.9m1.0m1.2m1.8m1.4m1.2m

Operating expense total

1.6m1.4m4.5m3.5m4.0m3.8m5.8m2.6m3.0m3.3m6.4m2.8m

Depreciation and amortization

7.5k478.1k610.5k655.7k6.2k5.8k5.8k6.6k5.8k27.4k26.7k26.7k
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Cash

255.0k2.0m1.6m8.9m

Prepaid Expenses

45.9k50.8k769.9k

Current Assets

3.0m2.0m1.6m9.7m

PP&E

11.3k52.0k79.8k460.7k
Quarterly
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

Net Income

(2.5m)(6.7m)(18.0m)(1.4m)

Depreciation and Amortization

675.8k8.3k25.3k68.0k

Accounts Payable

316.8k647.6k991.6k(1.7m)

Cash From Operating Activities

(1.2m)(5.2m)(10.8m)(12.3m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018

Net Income

(1.7m)(5.8m)(9.3m)(7.5m)(10.0m)(15.5m)(28.6m)(8.3m)(3.2m)(6.1m)(12.8m)

Depreciation and Amortization

24.6k478.1k1.1m1.7m12.5k13.7k19.5k6.6k12.4k39.8k54.7k81.5k

Accounts Payable

337.3k81.5k(3.4m)(3.1m)229.2k

Cash From Operating Activities

(1.2m)(432.9k)(7.5m)(9.4m)(3.4m)(6.2m)(10.1m)(5.8m)(7.7m)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Diffusion Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Diffusion Pharmaceuticals News and Updates

Diffusion Pharmaceuticals Chief Executive Officer David Kalergis to Present at 37th Annual J.P. Morgan Healthcare Conference

Industry’s Largest Symposium Brings Over 9,000 Attendees to San Francisco Industry’s Largest Symposium Brings Over 9,000 Attendees to San Francisco

Thinking about buying stock in Aurora Cannabis Inc, Belmond Ltd, Chesapeake Energy, Diffusion Pharmaceuticals Inc. or Johnson & Johnson?

NEW YORK, Dec. 17, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BEL, CHK, DFFN, and JNJ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Diffusion Pharmaceuticals Announces 1-for-15 Reverse Stock Split As Part Of NASDAQ Compliance Plan

CHARLOTTESVILLE, Va., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it’s needed most, today a…

Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

Highlights Include FDA Approval of Phase 2 On-Ambulance Clinical Trial for Treatment of Stroke and Appointment of New Chief Financial Officer

Diffusion Pharmaceuticals Chief Financial Officer William “Bill” Hornung to Present at 2018 BIO Investor Forum

Over 1,000 Attendees Expected; Opportunity to Learn About Company’s FDA Approval for Phase 2 On-Ambulance Stroke Trial and Phase 3 GMB Brain Cancer Trial Enrollment

Diffusion Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

CHARLOTTESVILLE, Va., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molecule trans sodium crocetinate (TSC), r…
Report incorrect company information

Diffusion Pharmaceuticals Company Life and Culture

Report incorrect company information

Diffusion Pharmaceuticals Frequently Asked Questions

  • When was Diffusion Pharmaceuticals founded?

    Diffusion Pharmaceuticals was founded in 2001.

  • Who are Diffusion Pharmaceuticals key executives?

    Diffusion Pharmaceuticals's key executives are David Kalergis, Ben Shealy and David Jones.

  • How many employees does Diffusion Pharmaceuticals have?

    Diffusion Pharmaceuticals has 11 employees.

  • Who are Diffusion Pharmaceuticals competitors?

    Competitors of Diffusion Pharmaceuticals include Vedanta Biosciences, ADC Therapeutics and Therapeutic Solutions International.

  • Where is Diffusion Pharmaceuticals headquarters?

    Diffusion Pharmaceuticals headquarters is located at 400 1317 Carlton Ave, Charlottesville.

  • Where are Diffusion Pharmaceuticals offices?

    Diffusion Pharmaceuticals has an office in Charlottesville.

  • How many offices does Diffusion Pharmaceuticals have?

    Diffusion Pharmaceuticals has 1 office.